Loading...
•
Jun 30, 2025
Twist Bioscience Q3 2025 Earnings Report
Twist Bioscience posted record Q3 revenue and returned to profitability.
Key Takeaways
Twist Bioscience delivered strong results in Q3 2025 with record revenue, improved gross margins, and a swing to net income, driven by solid performance in both SynBio and NGS segments.
Revenue by Segment
Forward Guidance
Twist expects continued revenue growth and margin improvements in Q4 FY25, aiming to achieve adjusted EBITDA breakeven by the end of FY26.
Positive Outlook
- Q4 revenue guidance of $96M–$98M
- Gross margin expected to rise to 51%–52%
- Full-year revenue guidance raised to $374M–$376M
- Adjusted EBITDA loss narrowed compared to prior guidance
- Ongoing product expansion and collaborations support future growth
Challenges Ahead
- Adjusted EBITDA still negative in near term
- Continued high SG&A expenses
- SynBio growth slower than NGS
- Free cash flow not reported
- No breakout of geographical revenue data
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...